Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26608375 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL21223482 | 0.77 | NOS3 (0.38) | POLB | |
| SCHEMBL30915338 | 0.77 | NOS3 (0.38) | POLB | |
| SCHEMBL26841823 | 0.75 | KDM4E (0.37) | SMN1; SMN2ALDH1A1MAPK1POLBHPGD | |
| SCHEMBL10412021 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL10411734 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL10412144 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL22251108 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL14853025 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL29513014 | 0.71 | POLB (0.53) | SMN1; SMN2ALDH1A1MAPK1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | SMN1; SMN2 1713/4885ALDH1A1 2871/4885MAPK1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.